ABL Bio

At a glance

ABL Bio filed 50 disclosures in the last 12 months, including 11 5% holder and 2 issuance. The most recent key filing was on Oct 16: A major holder's stake fell from 24.54% to 24.53% (open-market sale).

Revenue for 2025 was ₩79.3B, up 137.6% on 2024. It made an operating loss of ₩40.4B. Debt was 79% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩32.8B and operating loss of ₩34B.

The 2025 annual report lists 108 employees with an average tenure of 5.2 years and average pay of ₩125.4M, #66 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩375M each on average. It paid no cash dividend for 2025. 이상훈 and related parties held 24.90% at year end.

Of 1 recent 5%+ holder report, 0 raised and 1 cut a stake; the largest stake reported was 24.53% on Oct 16.

From the 2025 annual report

Staff: 108 (45 men, 63 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩13.4B. Directors and auditors: 6, paid ₩2.3B in total.

No cash dividend was paid for 2025.

Largest shareholder

이상훈 holds 23.02%; with 13 related parties the group holds 24.90% of common shares at year end (from 27.14% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼정회계법인 · opinion: Unqualified.

Rankings: Average pay #66 of 1,829

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports